ArticleScientific reports2025
Association of diabetic ketoacidosis and retinopathy in patients with type 2 diabetes: a nationwide cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic ketoacidosis (DKA) is the most common acute complication in people with diabetes. We aimed to assess the association of DKA with the risk of diabetic retinopathy (DR) and related ophthalmic interventions in individuals with type 2 diabetes (T2D). To ensure similar T2D management and severity at baseline between groups, we enrolled 1,007 T2D patients with and without DKA matched by anti-diabetic combination within the initial 3 months of diabetes diagnosis, gender, birth and diabetes diagnosis year in Taiwan National Health Insurance Research Database from 2000 to 2019. We employed Fine and Gray competing risk model to assess the risk of non-proliferative DR (NPDR), proliferative DR (PDR) and panretinal photocoagulation (PRP). Our results showed that patients with DKA had an increased risk of DR (adjusted subdistribution hazard ratio [SHR] 1.64 [95% CI, 1.34-2.01]) and PRP (SHR 1.43 [1.11-1.86]). The risk of NPDR is elevated when diabetes-to-DKA duration exceeded 24 months (SHR 2.15 [1.52-3.05]), while 1-24 months duration increased PDR risk (SHR 3.72 [1.76-7.88]). Patients with DKA onset at ages 46-55 and 56-65 showed specific PDR (SHR 1.82 [0.99-3.33]) and NPDR susceptibilities (SHR 6.52 [2.30-18.49]), respectively. Our study showed that DKA was associated with a higher risk of developing DR and requiring related ophthalmic interventions compared to a matched cohort with similar T2D baseline characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.